These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease. Mirshahi A; Namavari A; Djalilian A; Moharamzad Y; Chams H Ocul Immunol Inflamm; 2009; 17(1):59-64. PubMed ID: 19294576 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286 [TBL] [Abstract][Full Text] [Related]
29. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753 [TBL] [Abstract][Full Text] [Related]
30. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ Retina; 2009; 29(10):1396-403. PubMed ID: 19898177 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Bae JH; Lee CS; Lee SC Retina; 2011 Jan; 31(1):111-8. PubMed ID: 20856170 [TBL] [Abstract][Full Text] [Related]
32. Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections. Nuti E; Traversi C; Marigliani D; Balestrazzi A; Alegente M; Martone G; Malandrini A; Romeo N; Mazzotta C; Tosi GM Retina; 2011 Oct; 31(9):1863-70. PubMed ID: 21799465 [TBL] [Abstract][Full Text] [Related]
33. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Ehlers JP; Decroos FC; Fekrat S Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943 [TBL] [Abstract][Full Text] [Related]
35. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Chung EJ; Roh MI; Kwon OW; Koh HJ Retina; 2008; 28(7):957-63. PubMed ID: 18698297 [TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Solaiman KA; Diab MM; Abo-Elenin M Retina; 2010; 30(10):1638-45. PubMed ID: 20838357 [TBL] [Abstract][Full Text] [Related]
37. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Akinci A; Batman C; Ozkilic E; Altinsoy A Retina; 2009; 29(10):1432-5. PubMed ID: 19898181 [TBL] [Abstract][Full Text] [Related]
38. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Velez-Montoya R; Fromow-Guerra J; Burgos O; Landers MB; Morales-Catón V; Quiroz-Mercado H Retina; 2009 Jan; 29(1):20-6. PubMed ID: 18784623 [TBL] [Abstract][Full Text] [Related]
39. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585 [TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]